Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone.

T. Ponnapakkam, R. Katikaneni, T. Nichols, G. Tobin, J. Sakon, Osamu Matsushita, R. C. Gensure

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Most chemotherapeutics reduce bone mineral density (BMD) and increase risk for fractures by causing gonadal suppression, which in turn increases bone removal. Cyclophosphamide (CYP) also has a direct effect of inhibiting bone formation and removal, making the resulting bone loss particularly difficult to treat with antiresorptive therapy. We tested whether a single dose of the anabolic agent PTH linked to a collagen binding domain (PTHCBD) could prevent the effects of CYP-induced bone loss. Mice received either buffer alone, CYP, or CYP+ PTH-CBD. BMD and alkaline phosphatase were measured every 2 weeks for a total of 8 weeks. After 6 weeks, mice treated with CYP showed expected reductions in BMD (increase from baseline: 7.4 ± 6.9 vs 24.35 ± 4.86% in mice without chemotherapy, p

Original languageEnglish
JournalJournal of Endocrinological Investigation
Volume34
Issue number11
Publication statusPublished - Dec 2011
Externally publishedYes

Fingerprint

Parathyroid Hormone
Cyclophosphamide
Osteoporosis
Drug Therapy
Bone Density
Bone and Bones
Anabolic Agents
Osteogenesis
Alkaline Phosphatase
Buffers
Collagen
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone. / Ponnapakkam, T.; Katikaneni, R.; Nichols, T.; Tobin, G.; Sakon, J.; Matsushita, Osamu; Gensure, R. C.

In: Journal of Endocrinological Investigation, Vol. 34, No. 11, 12.2011.

Research output: Contribution to journalArticle

Ponnapakkam, T. ; Katikaneni, R. ; Nichols, T. ; Tobin, G. ; Sakon, J. ; Matsushita, Osamu ; Gensure, R. C. / Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone. In: Journal of Endocrinological Investigation. 2011 ; Vol. 34, No. 11.
@article{baa26b2529bf4b5f85bf425cc5e28b5b,
title = "Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone.",
abstract = "Most chemotherapeutics reduce bone mineral density (BMD) and increase risk for fractures by causing gonadal suppression, which in turn increases bone removal. Cyclophosphamide (CYP) also has a direct effect of inhibiting bone formation and removal, making the resulting bone loss particularly difficult to treat with antiresorptive therapy. We tested whether a single dose of the anabolic agent PTH linked to a collagen binding domain (PTHCBD) could prevent the effects of CYP-induced bone loss. Mice received either buffer alone, CYP, or CYP+ PTH-CBD. BMD and alkaline phosphatase were measured every 2 weeks for a total of 8 weeks. After 6 weeks, mice treated with CYP showed expected reductions in BMD (increase from baseline: 7.4 ± 6.9 vs 24.35 ± 4.86{\%} in mice without chemotherapy, p",
author = "T. Ponnapakkam and R. Katikaneni and T. Nichols and G. Tobin and J. Sakon and Osamu Matsushita and Gensure, {R. C.}",
year = "2011",
month = "12",
language = "English",
volume = "34",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",
number = "11",

}

TY - JOUR

T1 - Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone.

AU - Ponnapakkam, T.

AU - Katikaneni, R.

AU - Nichols, T.

AU - Tobin, G.

AU - Sakon, J.

AU - Matsushita, Osamu

AU - Gensure, R. C.

PY - 2011/12

Y1 - 2011/12

N2 - Most chemotherapeutics reduce bone mineral density (BMD) and increase risk for fractures by causing gonadal suppression, which in turn increases bone removal. Cyclophosphamide (CYP) also has a direct effect of inhibiting bone formation and removal, making the resulting bone loss particularly difficult to treat with antiresorptive therapy. We tested whether a single dose of the anabolic agent PTH linked to a collagen binding domain (PTHCBD) could prevent the effects of CYP-induced bone loss. Mice received either buffer alone, CYP, or CYP+ PTH-CBD. BMD and alkaline phosphatase were measured every 2 weeks for a total of 8 weeks. After 6 weeks, mice treated with CYP showed expected reductions in BMD (increase from baseline: 7.4 ± 6.9 vs 24.35 ± 4.86% in mice without chemotherapy, p

AB - Most chemotherapeutics reduce bone mineral density (BMD) and increase risk for fractures by causing gonadal suppression, which in turn increases bone removal. Cyclophosphamide (CYP) also has a direct effect of inhibiting bone formation and removal, making the resulting bone loss particularly difficult to treat with antiresorptive therapy. We tested whether a single dose of the anabolic agent PTH linked to a collagen binding domain (PTHCBD) could prevent the effects of CYP-induced bone loss. Mice received either buffer alone, CYP, or CYP+ PTH-CBD. BMD and alkaline phosphatase were measured every 2 weeks for a total of 8 weeks. After 6 weeks, mice treated with CYP showed expected reductions in BMD (increase from baseline: 7.4 ± 6.9 vs 24.35 ± 4.86% in mice without chemotherapy, p

UR - http://www.scopus.com/inward/record.url?scp=84862554482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862554482&partnerID=8YFLogxK

M3 - Article

C2 - 21750397

AN - SCOPUS:84862554482

VL - 34

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 11

ER -